Edge Capital Group’s DexCom DXCM Stock Holding History

Edge Capital Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,055	Closed	-$123K	–	336
2023 Q1	$123K	Buy	+1,055	New	+$118K	0.01%	329

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Edge Capital Group's DXCM Position: Q2 2023 in Review

Edge Capital Group sold out of DexCom (DXCM) in Q2 2023, closing a stake of 1,055 shares — an estimated $123K sold.

Edge Capital Group first reported a position in DXCM in Q1 2023 and held it in 1 quarter. The position peaked at $123K in Q1 2023. 954 funds tracked by Wall St. Rank hold DXCM as of Q2 2023.

Edge Capital Group reported no remaining DexCom position as of Q2 2023 after selling out during the quarter.
Edge Capital Group sold 1,055 DexCom shares in Q2 2023, an estimated $123K.
Edge Capital Group first reported a position in DexCom in Q1 2023 and held it in 1 quarter.
Edge Capital Group's DexCom position peaked at $123K in Q1 2023.
954 funds tracked by Wall St. Rank held DexCom as of Q2 2023.

Based on Edge Capital Group's 13F filing for Q2 2023, filed 8 Aug 2023.